Medical Regulation in Special Jurisdictions

The trade-off inside every approval regime

Modern drug regulation dates from a specific disaster. Thalidomide caused severe birth defects in thousands of children, and the American response, the Kefauver-Harris Amendment of 1962, added proof of effectiveness to the existing requirement of proof of safety. Nearly every argument in this field is an argument about that amendment.

The case for it was earned in the worst possible way. The case against it is that regulators face an asymmetry: the harm from approving a bad drug is visible and attributable, while the harm from delaying a good one falls on people nobody can name. Daniel Klein and Alex Tabarrok’s survey of that literature is the standard reference. The accounting is genuinely difficult. Roughly eight per cent of drugs that enter human trials are eventually approved, and estimates of what it costs to bring one to market range from a few hundred million dollars to well over two billion, depending on whether the cost of capital and the failures are counted.

What a special jurisdiction actually changes

Próspera in Honduras is the most developed example. Its framework does not abolish regulation, it makes it selectable. A medical business there can operate under Honduran rules, adopt the regime of a recognised regulator such as the FDA, the EMA, Japan’s PMDA or Health Canada, propose a bespoke framework for approval, or fall back on common-law liability with enhanced damages. The distinctive part is who checks compliance: providers must carry regulatory insurance, and the insurer inspects, because the insurer pays when something goes wrong. Niklas Anzinger, who works on this inside Próspera, describes it as an opt-in parallel lane rather than a replacement for the FDA.

The same logic turns up without leaving the developed world. Dubai Healthcare City has run its own health regulator since 2002. Montana began licensing experimental treatment centres in 2025, allowing supply of therapies that have completed only early-phase trials, under written informed consent. Japan created a conditional approval route for regenerative products in 2014, and the European Union has granted conditional marketing authorisations for close to two decades.

Approval, liability and the space between

Prior approval is not the only way to hold a treatment to account, and the alternatives special jurisdictions reach for fall into three families. The first is liability: a provider may act freely but answers fully for the harm it causes, with damages heavy enough to concentrate the mind. The second is insurance, which is Próspera’s distinctive move, since an insurer who has to pay out has a direct financial reason to inspect a protocol before it is used and none at all to wave a bad one through. The third is disclosure, where the authority certifies rather than prohibits, publishes what is known, and leaves the decision with the patient and the doctor. Jessica Flanigan has made the fullest philosophical case for that last approach.

Each of them needs something in place to work. Liability needs courts that can enforce a judgment. Insurance needs insurers who are independent of the people they inspect. Certification needs someone credible doing the testing. That is why the subject belongs under governance rather than under medicine: what a jurisdiction is really choosing is which institution it trusts to do the checking, and whether that institution has any reason to be careful.

It is also why the interesting cases are not all offshore. Montana began licensing experimental treatment centres in 2025 inside the ordinary American federal system. And the reform most often proposed is not the abolition of approval but its mutual recognition, so that a medicine cleared by one competent regulator need not be cleared again from scratch by the next.